The history of the global medical device industry demonstrates that mergers and acquisitions are a defining pathway for the growth of leading enterprises. International companies such as Medtronic have continuously strengthened their market positions and secured high-growth opportunities through strategic acquisitions. Today, China’s medical device industry is entering a new phase of consolidation and collaborative development.

Recently, Kossel Medtech (Suzhou) Co., Ltd. (“Kossel”), a platform-based company in the vascular intervention sector, completed a strategic acquisition of the peripheral vascular intervention business of Shanghai Biotriton Medical Technology Co., Ltd. (“Biotriton Medical”). This acquisition further enhances Kossel’s one-stop solution capability in the peripheral intervention field and marks another important step in the company’s transformation from a technology follower to an ecosystem builder, accelerating its advancement toward the global stage.

Strategic M&A Empowering Global Expansion of China’s Peripheral Intervention Industry

The medical device industry is characterized by long value chains and multiple interconnected segments. The sector has now entered a phase of structural oversupply, with each sub-segment comprising dozens or even hundreds of competitors, while core technologies remain fragmented across different players.

In this context, competition has become increasingly complex. Platform-based companies capable of integrating the full value chain, coordinating upstream and downstream resources, and achieving global scalability have become increasingly scarce strategic assets.
Unlike the innovation-driven biotech model centered on blockbuster products, medical device BD (business development) is fundamentally about building a complete clinical value chain—providing an integrated toolset for surgical procedures, particularly in highly procedural fields such as vascular intervention.

BD capability has therefore become a key indicator of a company’s long-term strategic potential. It represents a critical bridge from internal value creation to external value realization, and a historic opportunity for China’s medical device industry to accelerate global expansion, resource integration, and technological upgrading.
According to the 2025 China Health Industry White Paper, China’s medical device M&A transaction volume reached RMB 75 billion in 2024, increasing 82% year-on-year, significantly outpacing the global average growth rate of 6%–10%.

Importantly, M&A should not be driven by trends alone. The core value of BD lies in strengthening and completing clinical capability chains. All strategic actions must ultimately return to clinical needs and benefit patients.

Kossel’s acquisition of Biotriton Medical is a concrete implementation of this clinical value-chain strategy, enabling ecosystem-level integration in the peripheral intervention field and delivering a more complete and optimized one-stop solution for physicians and patients.

Building an Integrated Ecosystem Across the Full Spectrum of Peripheral Vascular Disease Care

Compared with coronary intervention, peripheral vascular intervention involves a wider range of vessel types, greater anatomical variability, and more diverse procedural requirements. No single product or technology can fully cover the entire treatment workflow. In addition, peripheral vascular diseases are often characterized by complex progression and hidden early symptoms, resulting in relatively low treatment penetration rates.

At the same time, global aging trends are expanding the patient population, creating significant long-term growth potential for the peripheral intervention market. According to Frost & Sullivan, China’s peripheral intervention market remains in an early stage of development and is expected to exceed RMB 30 billion by 2030, with a CAGR of approximately 20%.

Peripheral Vascular Intervention Market Size, 2015–2030E (Source: Frost & Sullivan)

Given the limitations of single-product markets and the significant potential of integrated solution-driven demand, only through strategic collaboration, M&A, and ecosystem building can companies achieve sustainable, long-term growth while delivering better clinical outcomes.

• Accelerating Integrated Precision Diagnosis and Treatment

The competitive landscape of peripheral vascular intervention is undergoing a fundamental shift. Clinical value is no longer defined by the performance of individual devices, but by the ability to provide a complete “diagnosis–decision–treatment” workflow for complex procedures.

Kossel’s development trajectory reflects this industry evolution. Since 2013, the company has focused on therapeutic innovation, building a strong product portfolio including the Octoparms® Vena Cava Filter, the K-Rhino™ Thrombectomy Aspiration System, and the Tanghulu® PTA Balloon Dilatation Catheter, establishing leadership in venous disease treatment, thrombectomy, and vessel preparation.

The acquisition of Biotriton Medical is primarily aimed at strengthening the critical diagnostic imaging segment within the vessel.

Biotriton Medical’s independently developed K-VisionMax™ single-use peripheral intravascular ultrasound (IVUS) catheter and imaging system represents a leading domestic technology platform. It enables real-time three-dimensional visualization of vessel lumen, vessel wall, and surrounding structures, significantly improving intraoperative decision-making accuracy and long-term patient outcomes.

The deep integration of diagnostic and therapeutic tools will further accelerate Kossel’s development of an integrated precision treatment ecosystem.

K-VisionMax™ single-use peripheral intravascular ultrasound (IVUS) catheter and imaging system

• Expanding Full-Cycle Solutions for Peripheral Arterial and Venous Disease

Beyond IVUS technologies, Biotriton Medical has also developed a broad portfolio of active and passive interventional devices. Its ultrasonic shockwave guidewire enables effective recanalization of chronic total occlusions (CTOs) in both coronary and peripheral vessels.

Its ultrasound-based varicose vein treatment system addresses a billion-yuan-scale niche market, offering a non-invasive treatment alternative. The company also develops combination ultrasound thrombolysis systems and vascular interventional surgical robotic platforms.

These products are highly complementary to Kossel’s existing peripheral intervention portfolio, together forming a comprehensive, full-cycle integrated solution for arterial and venous disease management.

• Synergy in Timing, Strategy, and Team Integration

This acquisition demonstrates strong synergy in timing, strategic fit, and organizational alignment.

From a timing perspective, the intravascular ultrasound segment in peripheral intervention remains in a relatively early stage of competition, with significant room for growth. K-VisionMax™ has already obtained Class III medical device registration, while the IVUS system is in the registration process, positioning the company for imminent commercial acceleration.

From a team perspective, Biotriton Medical initially pursued an independent development path. However, in response to evolving industry dynamics, the team chose to embrace a broader platform strategy and collaborate with Kossel to advance shared long-term goals.

This synergy enables both companies to maximize the value of the acquisition while achieving sustainable growth in a high-potential market.

From Milestone to New Journey: Kossel’s Global Ecosystem Strategy

This transaction is not an isolated event, but another validation of Kossel’s dual-engine strategy of “independent innovation + ecosystem integration.”

Over its 13-year development history, Kossel has evolved from a single-product innovator in vena cava filters to a diversified platform company covering peripheral intervention, electrophysiology, coronary intervention, and core medical materials.

The company has also completed multiple strategic milestones, including its first overseas acquisition of Ireland-based Micell, enabling global regulatory access and commercialization, and now domestic ecosystem integration through Biotriton Medical to enhance its diagnostic capabilities.

Kossel’s Integrated Platform: Peripheral, Coronary, Electrophysiology & Core Materials

In the era of volume-based procurement, market competition has fundamentally shifted back to value creation. Leveraging strong technological innovation, reliable product quality, and extensive clinical experience, Kossel has repeatedly secured inclusion in national and provincial procurement programs.

In early 2026, Kossel announced a strategic partnership with Medtronic, further demonstrating its unique development path focused on patient-centered care, integrated solutions, and long-term collaboration.

Kossel stated that the acquisition of Biotriton Medical represents a key step in strengthening its one-stop peripheral intervention system. By integrating Biotriton’s strengths in diagnostic imaging with Kossel’s therapeutic portfolio, the company has established a comprehensive solution covering the full spectrum of peripheral vascular disease.

Looking ahead, Kossel will continue to pursue its dual-engine strategy of “independent innovation + ecosystem integration,” driving China’s vascular intervention industry toward the global high end of the value chain through long-term strategic commitment.

Biotriton Medical stated that the partnership represents a significant opportunity for complementary strengths and collaborative growth. Its expertise in precision diagnostics will be fully integrated into Kossel’s ecosystem, enabling continued innovation in the peripheral intervention field and contributing to the upgrading of China’s vascular intervention industry.

Without M&A, there is no industrial giant. However, more important than acquisitions themselves is the clarity of strategic intent and post-merger integration pathways. History has repeatedly proven this principle through the century-long evolution of global industry leaders.

Looking ahead, Kossel will continue to uphold its corporate values of pragmatism, efficiency, collaboration, sharing, perseverance, and dedication, while strengthening systematic innovation management to accelerate product development and deliver integrated clinical solutions, steadily advancing toward its goal of becoming a global leader in vascular intervention.